Akorn settles with FTC to allow VersaPharm merger

05-08-2014

Akorn settles with FTC to allow VersaPharm merger

Brues / Shutterstock.com

US-based injections maker Akorn has agreed to sell its rights to develop, manufacture and market generic tuberculosis injection rifampin to Watson Laboratories to settle charges by the US Federal Trade Commission (FTC) that its proposed acquisition of pharmaceutical company VersaPharm was likely to be anticompetitive.


Akorn, VersaPharm, FTC, mergers and acquisitions, tuberculosis

LSIPR